Chemical Profiling and Biological Activity of Two Tunicate-Associated Marine Bacteria by Yankova, Lyubina
University of Connecticut
OpenCommons@UConn
Honors Scholar Theses Honors Scholar Program
Spring 5-9-2014
Chemical Profiling and Biological Activity of Two
Tunicate-Associated Marine Bacteria
Lyubina Yankova
University of Connecticut - Storrs, Lcy681@gmail.com
Follow this and additional works at: https://opencommons.uconn.edu/srhonors_theses
Part of the Biology Commons, Medicinal Chemistry and Pharmaceutics Commons, Natural
Products Chemistry and Pharmacognosy Commons, Other Chemicals and Drugs Commons, and
the Other Microbiology Commons
Recommended Citation
Yankova, Lyubina, "Chemical Profiling and Biological Activity of Two Tunicate-Associated Marine Bacteria" (2014). Honors Scholar
Theses. 336.
https://opencommons.uconn.edu/srhonors_theses/336
  
 
 
 
 
 
 
Chemical Profiling and Biological Activity of Two Tunicate-Associated 
Marine Bacteria 
 
 
 
 
 
 
 
 
 
Author: Lyubina C. Yankova 
Advisor: Marcy J. Balunas Ph.D. 
University of Connecticut Honors Program 
Date Submitted: 5/9/2014 
2 
List of Abbreviations 
HPLC-MS: High Performance Liquid Chromatography-Mass Spectrometry 
NMR: Nuclear Magnetic Resonance 
BioMAP: Antibiotic Mode of Action Profile 
MSSA: Methicillin-sensitive Staphylococcus aureus 
MRSA: Methicillin-resistant Staphylococcus aureus 
MIC: Minimum Inhibitory Concentration  
IO: Instant Ocean 
DI: Deionized 
DCM: Dichloromethane 
DMSO: Dimethyl sulfoxide 
SPE: Solid Phase Extraction 
ISP4: Inorganic Salts-Starch Agar 
CDCl3: Deuterated Chloroform 
1
H NMR: Proton Nuclear Magnetic Resonance 
CHX: cycloheximide 
NDA: nalidixic acid 
MeOH: methanol 
 
 
 
  
3 
Abstract 
Marine natural products have recently been an increasingly abundant source of 
novel antibiotics. Given that there is an increasing resistance to current drug therapies, 
finding new sources such as marine natural products is essential. Tunicate-associated 
marine bacteria can be a significant source of antibacterial compounds. Two tunicates of 
the species Eudistoma were collected from Portobelo National Park on the Salmedina 
Reef of Panama in the Caribbean Sea. Bacteria associated with the tunicate were isolated, 
cultured, extracted, and fractionated. Fractions were tested against an array of clinically 
relevant bacterial pathogens in the BioMAP assay. Two fractions MB0086E and 
MB0088E demonstrated activity and specificity against Staphylococcus aureus, 
Enterococcus faecium, and Listeria ivanovii. This study focuses on developing the 
chemical profiles of the fractions using High Performance Liquid Chromatography and 
Nuclear Magnetic Resonance as well as further examining their biological activity using 
various assays.  
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Introduction    
                                          
 Although natural products from land species have been extensively studied, 
many more remain undiscovered in aquatic life. Natural compounds can provide starting 
structures for synthetic chemists to modify in order to make them less cytotoxic or more 
potent (Genilloud et al. 2011). Most microorganisms produce secondary metabolites, 
organic compounds that are not directly involved in the main functions of an organism’s 
survival. Instead, these metabolites often assist in the increase of an organism’s lifespan, 
ability to survive, and overall success in their environment. Marine microorganisms may 
provide biologically active compounds distinct from those discovered in terrestrial 
microorganisms, because their environmental conditions are substantially different 
(Subramani and Aalbersberg 2011).   
  
Figure 1. Diagram of a tunicate (figure from Hosie 2014). 
 Tunicates, also known as ascidians, are marine organisms that contain a 
significant amount of microbes. Tunicates get their name from the tunic-like sac (Figure 
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1) that surrounds them (Davidson 1993). They are also sometimes referred to as sea 
squirts because of the water they eject. These organisms are vulnerable to predation since 
they are often bright, attractive, and stationary. Since they have no escape mechanism, 
they must rely on producing chemical toxins to ward off predators (Flam 1994). Some of 
these toxins are produced by bacterial flora associated with the tunicates.  
 Many antibacterial compounds have previously been isolated from tunicates 
or tunicate-associated marine bacteria. Figure 2 displays antibacterial compounds isolated 
from tunicates or tunicate-associated marine bacteria discovered between 2010 and the 
present. Antibacterial activity was observed in brominated rubrolides 1-4 which were 
isolated from an African ascidian Synoicum globosum (Sikorska et al. 2013). 
Peptidolipins 5-9, lipopeptide compounds produced by the Nocardia sp. bacteria from the 
Florida Keys tunicate Trididemnum orbiculatum, showed activity against methicillin-
sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus 
(MRSA) (Wyche et al. 2012). N-deacetylshermilamine B 10, cystodimine A 11, and 
cystodimine B 12 are three pyridoacridine alkaloid compounds isolated from the 
Mediterranean ascidian Cystodytes dellechiajei, which are active against Escherichia coli 
and Micrococcus luteus (Bontemps et al. 2010). Synoxazolidinone A 13, an alkaloid 
isolated from Norwegian ascidian Synoicum pulmonaria, is active against 
Corynebacterium glutamicum (Tadesse 2010).  
BioMAP (antibiotic mode of action profile), an assay developed by the Linington 
lab at the University of California in Santa Cruz, is an efficient method for screening 
extracts against multiple bacterial pathogens. The assay assigns biological “fingerprints” 
to both known antibiotics and extracts. These “fingerprints” indicate against which of the  
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Figure 2. Recent antibacterial compounds isolated from tunicates (ascidians) or tunicate-
associated bacteria.  
clinically relevant bacterial pathogens the antibiotics show activity. Both Gram-positive 
and Gram-negative bacteria are included in the assay. An example of BioMAP shown in 
Figure 3 displays the varying levels of activity of various compounds against the bacterial 
pathogens. The figure indicates activity based on a range of shades from black (inactive) 
to red (highly active).  BioMAP also clusters the known antibiotics and extracts by 
structural class. The structural class can often be determined by the biological activity, 
since antibiotics from the same structural class usually implement similar mechanisms 
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Figure 3. BioMap. Extracts MB0088E and MB0086E were tested against 14 organisms 
(listed on map) and placed next to compounds of similar antimicrobial activity. In this 
cluster heat map, the shade of red depicts degree of antimicrobial activity (brighter shades 
show stronger activity). MB0088E and MB0086E show possible activity against 
Staphylococcus aureus, Listeria ivanovii, and Enterococcus faecium as well as similar 
activity to the compound ornidazole (courtesy of Linington lab). 
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for inhibiting bacterial growth. This assay is informative for two reasons: discovering the 
activity of extracts against clinically relevant bacterial pathogens and determining their 
possible structural classes (Wong et al. 2012). 
Recently, our lab tested extracts and fractions from tunicate-associated bacteria in 
the BioMAP assay and found two fractions with interesting activity. The sources of these 
fractions were two Panamanian tunicates of the species Eudistoma (Figure 4), collected 
from Portobelo National Park on the Salmedina Reef in the Caribbean Sea at a depth of 
50-60 feet. The bacteria associated with the tunicates were isolated and grown in liquid 
culture. The liquid cultures were then extracted and fractionated to be prepared for 
biological testing. The extracts and fractions were sent to the Linington lab at the 
University of California in Santa Cruz where they were tested in BioMAP (Figure 3). Our 
active fractions, labeled MB0086E and MB0088E, are grouped on the right side of the 
cluster heat map with ornidazole, due to their similar activity. Ornidazole is used to treat 
protozoan diseases such as giardiasis, trichomoniasis, and bacterial vaginosis (Saracoglu 
et al. 1998; Ozbilgin et al. 2004; Inceboz et al. 2004). 
 
 
 
 
 
Figure 4. A representative Eudistoma sp. (“strawberry tunicate”) collected from 
Portobelo National Park on the Salmedina Reef in Panama (photo Marcy Balunas). 
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In the BioMAP assay, these fractions showed potent activity against 
Staphylococcus aureus, Enterococcus faecium, and Listeria ivanovii (Figures 3 and 5). S. 
aureus can cause severe skin infections (Lowy 1998); E. faecium causes urinary tract 
infections (Huycke et al. 1998); and L. ivanovii is a ruminant pathogen (Fentahun and 
Fresebehat 2012). Notably, the fractions were not active against the entire panel of 
bacterial pathogens in the BioMAP assay. This indicates that the active compounds in the 
fractions are selective. This is beneficial because compounds intended for an antibiotic 
which are specific to only a few types of bacteria are more desirable. Specificity is crucial 
since antibacterial compounds should not disrupt or kill host cells or non-pathogenic 
bacterial strains. Non-specific, or broad-spectrum antibiotics, can contribute to drug 
resistance by allowing the growth and spread of bacteria which are not susceptible to that 
antibiotic (Huycke et al. 1998).  
The activity shows potential for a possible new antibiotic for humans and/or 
cattle. S. aureus is a common Gram-positive coccal bacterium in skin infections that 
causes sores. S. aureus can also cause the sometimes fatal toxic shock syndrome, 
endocarditis, and sepsis (Lowy 1998). In addition, once a human is infected with the 
bacteria, they become more susceptible to future infections.  Even though antibiotics for 
S. aureus already exist, new antibiotics are always desired that are selective and help the 
issue of growing resistance to current antibiotics (Giedraitiene et al. 2011).  
The other human pathogen that the fractions show activity against, E. faecium, is 
one of the primary bacteria causing urinary tract infections. Other complications these 
Gram-positive bacteria may cause are bacteremia and surgical wound infections. 
Infections from strains that originate in the body’s normal flora are usually easily treated; 
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however, strains originating from nosocomial infections are likely to be antibiotic 
resistant and therefore more difficult to treat (Huycke et al. 1998). The antibiotic resistant 
strains make the search for novel antibiotic compounds crucial to treating future 
infections.  
 
 
 
 
 
 
 
 
 
Figure 5. BioMap profile of MB0088E and MB0086E with normalized MIC values 
(courtesy of Linington lab). 
L. ivanovii, the third bacteria which the fractions are active against, mainly affects 
ruminants. L. ivanovii are Gram-positive bacilli. Infection by L. ivanovii in ruminants 
may cause abortions (Fentahun and Fresebehat 2012). This pathogen rarely affects 
humans; however, recent cases of L. ivanovii causing gastroenteritis and bacteremia have 
been reported (Guillet et al. 2010). Another species in the same genus, Listeria 
monocytogenes, can cause listeriosis in humans. L. monocytogenes is a food-borne 
pathogen that could be fatal. This species may also cause abortions in pregnant women 
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(Lamont et al. 2011). If the active fractions target a mechanism implemented by all 
bacteria of the Listeria genus, then they may inhibit L. monocytogenes as well.  
The bacterium from which MB0086E was extracted is an Actinomycete. 
MB0088E may be an Actinomycete as well, although this is not as clear from the 
bacteria’s morphology. Actinomycetes are an especially significant source of biologically 
active compounds. There is great diversity amongst these microorganisms and they have 
been previously shown to produce antibiotic compounds (Subramani and Aalbersberg 
2011). More than 22,000 secondary metabolites from microbes have been studied and 
70% of these come from Actinomycetes (Subramani and Aalbersberg 2011).  
The activity of fractions MB0086E and MB0088E against two human pathogens 
could be significant in the search for novel antibiotics. Drug resistant strains of human 
pathogenic bacteria are becoming an increasing threat, making these two fractions of 
valuable interest. E. faecium is intrinsically resistant to some antibiotics since the 
resistance is not acquired, but encoded in the bacterial genome. The surface penicillin 
binding proteins of E. faecium do not bind β-lactam antibiotics with high affinity 
(Giedriatiene et al. 2011). There are also vancomycin-resistant strains of E. faecium due 
to inducible genes which change the cell wall synthesis. These bacteria can become even 
more drug resistant through conjugation or plasmid transfer from other bacteria (Huycke 
et al. 1998). S. aureus can acquire resistance through similar methods. Drug resistant 
strains also contain new penicillin binding proteins that prevent β-lactam antibiotics from 
working. Vancomycin-resistant S. aureus strains are also on the rise (Lowy 1998).  
Currently, a solution to this problem is treating patients with multiple antibiotics 
simultaneously; however, this method has not been proven to be fully successful (Huycke 
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et al. 1998). Novel antibiotic compounds with specificity, such as the compounds present 
in MB0086E and MB0088E could be a superior solution.  
The goal is to further the research and data on the two bacteria, the compounds 
they produce, and their biological activity. The two bacteria must be regrown, extracted, 
and fractionated. The extracts and fractions will be tested again for biological activity 
against S. aureus. If the activity is found again in the new fractions, then the active 
compounds contained in the fractions will be isolated. Then we must determine if the two 
compounds are the same and whether or not they are analogs of ornidazole. Further 
research will focus on modifying the compound’s structure to achieve the optimal activity 
for use as an antibiotic against S. aureus, E. faecium, and L. ivanovii.  
 
Materials and Methods 
 
General Experimental Procedures 
Each extract and fraction was prepared at 1 mg/mL in either HPLC grade MeOH or 
acetonitrile for HPLC-MS or HPLC analysis. Samples were run on an Agilent ESI single 
quadrupole mass spectrometer connected to an Agilent HPLC system containing a G1311 
quaternary pump, G1322 degasser, and a G1315 diode array detector with an Eclipse 
XDB-C18 reverse phase-HPLC column. Fractions were dissolved in CDCl3 for 
1
H NMR 
analysis. 
1
H NMR analysis was conducted on a Brüker Avance 500 MHz spectrometer 
which gives chemical shifts in ppm downfield from TMS. 
 
Tunicate Collection, Plating, and Bacterial Isolation 
Tunicates were collected from Portobelo Park in Salmedina, Panama from the Caribbean 
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Sea (N 9 33.746 W 79 41.617) at a depth of 50-60 feet. Tunicates were rinsed with sterile 
sea water and cut into small pieces. Tunicates were homogenized by crushing with a 
mortar and pestle in 1-2 mL sterile sea water. A sterile cotton swab was dipped in 
homogenate and spread onto ISP4 agar (soluble starch 10 g, K2HPO4 1 g, MgSO4 USP 1 
g, NaCl 1 g, (NH4)2SO4 2 g, CaCO3 2g,  FeSO4 1 mg, MnCl2 1 mg, ZnSO4 1 mg, agar 20 
g, 1 L water) with cycloheximide (CHX) and nalidixic acid (NDA). Bacteria PTY138G1 
(Actinomycete) and PTY139L1 were selected from the ISP4 plates and further isolated 
on marine agar. Bacterial isolates were stored in liquid nitrogen.  
 
Regrowing of Bacteria 
PTY138G1 and PTY139L1 were removed from liquid nitrogen and streaked onto agar 
plates of various media in order to determine ideal growth conditions. PTY138G1 was 
streaked onto ISP4 agar (with DI, CHX, and NDA), ISP4 agar (with IO, CHX, and 
NDA), and marine agar (peptone 5 g, yeast extract 1 g, ferric citrate 0.1 g, NaCl 19.45 g, 
MgCl2 8.8 g, Na2SO4 3.24 g, CaCl2 1.8 g, KCl 0.55 g, NaHCO3 0.16 g, KBr 0.08 g, SrCl2  
34 mg,  H3BO3 22 mg, Na2(SiO2)nO 4 mg, NaF 2.4 mg,  NH4NO3 1.6 mg, Na2HPO4 8 
mg, agar 15 g, 1 L DI water). PTY139L1 was also streaked onto ISP4 agar (with IO, 
CHX, and NDA), ISP4 agar (with DI, CHX, and NDA) and marine agar. Plates were 
incubated for 1-2 weeks at 30° C.  
 
Bacterial growth in liquid culture 
Liquid media was prepared according to method and ingredients mentioned above, but 
without agar. ISP4 + DI water (1000 mL) and marine broth (1000 mL) were each 
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inoculated with single isolated colonies from the PTY138G1 plates. Marine broth (1000 
mL) was inoculated with single isolated colonies from the PTY139L1 plates. The flasks 
were incubated at 30° C with shaking, for two weeks. After removal from the incubator, 
each flask was streaked onto plates to check for purity of cultures.   
 
Extraction 
Diaion HP-20 beads (200 g) were first prepared by washing them in a frit filter with 
methanol and then water. The beads were then transferred to a 1 L flask where the liquid 
bacterial culture, PTY183G1 grown in marine broth or ISP4 broth, was also added. The 
flask was covered and shaken for 24 hours at 135 rpm. After 18-24 hours, the flask was 
removed from the shaker and prepared for extraction. The contents of the flask were 
poured into a frit filter set up on a vacuum flask. The water was removed by vacuum and 
the beads were washed two times with 600 mL of DI water, after allowing the water to sit 
in the filter for five minutes. The water layers were discarded. The beads were then 
washed with 600 mL of 100% MeOH, 600 mL of 100% DCM, and 600 mL of 100% 
acetone. The solvents were evaporated. The PTY138G1 extract grown in marine broth 
was named LY0086-MB and the PTY138G1 extract grown in ISP4 broth was named 
LY0086-ISP4.  
 
Fractionation 
The extracts LY0086-MB and LY0086-ISP4 were subject to fractionation using a 
Discovery DSC-18 reverse phase-solid phase extraction cartridge with a MeOH— H2O 
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solvent gradient (1:4, 1:1, 4:1, 100% MeOH, 100% Ace). The fractions were named 
LY0086-MB (A-E) and LY0086-ISP4 (A-E). 
 
Extraction/Fractionation 
A separate set of flasks of PTY138G1 and PTY139L1 liquid cultures (both grown in 
marine agar with the same method mentioned above) underwent a combined step of 
extraction and fractionation instead of sequential extraction followed by fractionation. 
Diaion HP-20 beads were first prepared by washing them in a frit filter with methanol 
and then water. The beads were then transferred to a 1 L flask where the liquid bacterial 
culture, either PTY183G1 (grown in marine broth) or PTY139L1, was also added. The 
flask was shaken for 24 hours at 135 rpm. After 18-24 hours, the flask was removed from 
the shaker and prepared for extraction. The contents of the flask were poured into a 600 
mL frit filter set up on a vacuum flask. The water was removed by vacuum and the beads 
were washed two times with 600 mL of DI water, after allowing the water to sit in the 
filter for five minutes. The water layers were discarded. The beads were then subject to 
an extraction/fractionation with a MeOH—H2O solvent gradient (1:4, 1:1, 4:1, 100% 
MeOH, 100% Ace), each with a volume of 600 mL. Solvents were allowed to sit in the 
frit filter with the beads for five minutes before vacuum was applied. The fractions from 
PTY138G1 were named LY0086 (A-E) and the fractions from PTY139L1 were named 
LY0088 (A-E). 
 
Bioassay procedure 
The 96 well plate bioassay procedure was modified from Zgoda and Porter (2001). 
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Day 1: 
5 mL of tryptic soy broth (Bacto™ Tryptone [Pancreatic Digest of Casein] 17 g, Bacto 
Soytone [Peptic Digest of Soybean Meal] 3 g, glucose 2.5 g, NaCl 5 g,        2.5 g, 1 
L DI water) were placed in two 15 mL Falcon tubes. One tube was inoculated with 1 
colony of methicillin-sensitive Staphylococcus aureus (MSSA) and the other tube was 
left to serve as a blank. The tubes were incubated for 18 hours at 37° C.  
Day 2: 
The blank was checked for absence of growth. Bacteria were diluted 1:1,000 with sterile 
water. A mix was then created with 2 mL inoculum, 8 mL tryptic soy broth, and 9.5 mL 
sterile water. Each well in a 96 well plate was filled with 195 μL of this mix (except for 
sterility control and color control wells). The assay was conducted at 500 μg/mL so 
extracts were prepared at 20 mg/mL with DMSO and 5 μL of the extract was added to the 
assay wells. Negative control wells contained 195 μL of the mix and 5 μL sterile DMSO. 
Positive control wells contained 195 μL mix and 5 μL of vancomycin at 200 μg/mL. 
Sterility control wells contained 80 μL broth, 115 μL sterile water, and 5 μL DMSO. 
Color control wells contained 80 μL broth, 115 μL sterile water, and 5 μL of the extract 
(Table 1). The negative, positive, and sterility controls had 8 wells each. The assay wells 
with the extract were performed in triplicate and the color control wells were performed 
in duplicate. The 96 well plate was then incubated for 24 hours at 37° C.  
Day 3: 
The 96 well plate was run on a Gen51.11 Plate reader. The plate was read at an 
absorbance of 750 nm.  
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Control Components 
Negative control 195 μL mix (inoculum, water, and broth) 
5 μL sterile DMSO 
Positive control 195 μL mix (inoculum, water, and broth) 
5 μL vancomycin (at 200 μg/mL) 
Sterility control 80 μL broth 
115 μL sterile water 
5 μL sterile DMSO 
Color control 80 μL broth 
115 μL sterile water 
5 μL extract 
Table 1. Components of 96 well plate bioassay controls. 
 
Disc Diffusion Assay 
The disc diffusion assay procedure was modified from Bauer et al. (1966). 
Day 1: 
A liquid S. aureus culture (100 μL) of optical density .0132 was plated uniformly on 
tryptic soy agar (Bacto™ Tryptone [Pancreatic Digest of Casein] 15 g, Bacto Soytone 
[Papaic Digest of Soybean Meal] 5 g, NaCl 5 g, agar 15 g, 1 L DI water). Fractions were 
prepared at 2 mg/mL and 5 mg/mL in DMSO. Discs were soaked in 10 μL of the 
prepared fractions and placed on S. aureus plates. Each fraction was tested in triplicate. 
Each plate contained one disc with 10 μL DMSO and one disc with 10 μL vancomycin to 
serve as controls. Plates were incubated for 18 hours at 37° C.  
Day 2: 
Plates were checked for zones of inhibition around discs. Diameters of zones of inhibition 
were measured in mm if present. 
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Results and Discussion 
 Bacteria were grown on various media to observe differences in growth and to 
determine the optimal growth conditions. PTY138G1 was grown on ISP4 + DI and ISP4 
+ IO plates. The bacteria were able to grow on both types of agar, but at different rates. 
The bacteria took one week to grow on ISP4 + DI, but two weeks to grow on ISP4 + IO. 
PTY138G1 was also grown on marine agar and compared to its growth on ISP4 + DI. 
The bacterial growth looked different on these two types of agar. On ISP4 + DI the 
colonies were clearly Actinomycetes with large gray centers and white outlines (Figure 
6A). The classification of PTY138G1 as an Actinomycete was not as clear on marine 
agar, and the colonies were small and black (Figure 6B). 
 
A)    B) 
 
Figure 6. PTY138G1 growth on agar (2 week incubation period at 30° C): (A) ISP4 agar 
with deionized water, and (B) marine agar with deionized water.        
The differences in growth amongst media were even more apparent when the 
bacteria were grown in liquid media. In liquid ISP4 + DI media, the surrounding media 
was opaque with floating white solid colonies (Figure 7A). In liquid marine broth, the 
19 
surrounding media was dark black with floating grey solid colonies (Figure 7B). The 
floating colonies were similar in size.  
A)   B)  
 
Figure 7. PTY138G1 growth in liquid media (2 week incubation period at 30°C): (A) 
ISP4 media with deionized water, and (B) marine broth with deionized water. 
 PTY139L1 was also grown on both ISP4 agar and marine agar. There was no 
growth on ISP4 agar with either DI or IO. The bacteria grew on marine agar and showed 
a color change after many weeks of incubation. After two weeks of growth, the bacteria 
consisted of small, dull orange colonies with an umbonate elevation (Figure 8A). This 
may be a sign that PTY139L1 is an Actinomycete as well. After more than four weeks of 
incubation, the colonies underwent a color change to black (Figure 8B). The color change 
was not clearly the result of the same compound that caused the black color in 
PTY138G1 in marine broth. 
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A)  B)                                                                
Figure 8. PTY139L1 growth on marine agar: A) 2 week incubation period at 30° C., and 
B) >4 weeks incubation at 30° C. 
 All samples were run on HPLC-MS or HPLC to compare metabolite profiles. The 
UV spectra of MB0086E (Figure 9) and MB0088E (Figure 10) (the original extracts used 
in BioMAP) were different from LY0086E (Figure 11) and LY0088E (Figure 12) (the 
new large scale extracts). Peaks of interest in MB0086E appear between minutes 50-56, 
69-71, and 22-24. Peaks of interest in MB0088E appear at minutes 23, 29, 41, 55, 69, 75. 
LY0086E and LY0088E both have interesting peaks at minutes 70, 74, and especially at 
64. Based on these peaks, there is a possibility that LY0086E and LY0088E contain the 
same compounds.  
MB0086E, MB0088E, LY0086E, and LY0088E were also all examined via 
1
H 
NMR in CDCl3. LY0086E and LY0088E both show possible aromatic rings between 7 
and 7.5 ppm (Figures 13 and 14). Comparison of the two 
1
H NMR spectra indicates that 
the two extracts are similar. However, LY0086E and LY0088E are not pure compounds, 
making this difficult to determine. The 
1
H NMR of MB0086E and MB0088E are difficult 
to evaluate, because the samples were small, giving an unclear baseline. However, the 
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Figure 9. UV chromatogram from HPLC-MS of original fraction MB0086E. 
 
Figure 10. UV chromatogram from HPLC-MS of original fraction MB0088E. 
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Figure 11. UV chromatogram from HPLC of new fraction LY0086E. 
Figure 12. UV chromatogram from HPLC of new fraction LY0088E. 
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Figure 13. 
1
H NMR of new fraction LY0086E in CDCl3. 
 
 
Figure 14. 
1
H NMR of new fraction LY0088E in CDCl3. 
two have similar spectra, indicating that the compounds may be the same or analogs. 
Based on the NMR, MB0086E and MB0088E are likely pure compounds. The two 
spectra also show similarities when compared to ornidazole’s NMR (Figure 17) predicted 
with ChemBioDraw Ultra 13.0 (PerkinElmer, Inc., Cambridge, Massachusetts, USA). 
The two compounds may be analogs of ornidazole, the structure of which is shown in 
Figure 18. 
24 
 
 
 
Figure 15. 
1
H NMR of original fraction MB0086E in CDCl3. 
 
 
 
Figure 16. 
1
H NMR of original fraction MB0088E in CDCl3. 
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Figure 17. Predicted 
1
H NMR of ornidazole. 
 
Figure 18. Structure of ornidazole. 
 Bioassays were conducted in order to determine if the newly extracted fractions 
(LY0086E and LY0088E) had the same activity as (MB0086E and MB0088E). The 
bioassay did not show activity against S. aureus compared to vancomycin. The bioassay 
often had high absorbance values in the color controls. This indicates that there was 
something in the extracts causing this absorbance. Growth was even sometimes observed 
in the color controls, even though there was no growth in the sterility controls. The high 
absorbance in the color controls could have been affecting the values for the wells in 
which the extracts were tested against S. aureus. After many attempts in which the color 
controls showed high absorbance values, the extracts were sterile filtered before the assay 
was performed. However, even after filtration, the extracts did not show activity against 
S. aureus (Figures 19 and 20). 
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Figure 19. Bioassay of fractions LY0086A, LY0086B, LY0086C, LY0086D, LY0086E 
against methicillin-sensitive Staphylococcus aureus (MSSA). In a 96 well assay, MSSA 
was incubated for 24 hours with the five fractions, vancomycin as the positive control, 
and DMSO as the negative control. No inhibition of MSSA growth occurred. 
Figure 20. Bioassay of fractions LY0088A, LY0088B, LY0088C, LY0088D, LY0088E 
against methicillin-sensitive Staphylococcus aureus (MSSA). In a 96 well assay, MSSA 
was incubated for 24 hours with the five fractions, vancomycin as the positive control, 
and DMSO as the negative control. No inhibition of MSSA growth occurred. 
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 After no activity was found, fractions LY0086E and LY0088E were sent to 
collaborators at the University of California, Santa Cruz in order to be tested in the assay 
in which MB0086E and MB0088E were originally active. The fractions still showed no 
activity against S. aureus, E. faecium, or L. ivanovii. In addition, the fractions LY0086A-
E, LY0088A-E, LY0086A-E (SPE fractions from bacteria grown in ISP4 media), and 
LY0086A-E (SPE fractions from bacteria grown in marine broth) were not found to be 
active against S. aureus in the disk diffusion assay at 2 mg/mL or 5 mg/mL. LY0086E 
and LY0088E were also not active in the disk diffusion assay at 10 mg/mL. 
An obvious obstacle in this experiment was the inability to repeat the activity 
previously shown in MB0086E and MB0088E. Many reasons could explain this 
inactivity. In the original experiment, fractions MB0086E and MB0088E could have been 
contaminated with something active that showed a false result in the BioMAP assay. The 
active compound might not have been produced in the new experiment. In the original 
experiment the bacteria were grown in 125 mL of media, which could have provided a 
better environment for the bacteria to produce these active fractions, whereas in the new 
one they were grown in 500 mL of media. The problem could also have been in the 
extraction of the bacteria. The active compounds may have remained on the HP-20 
Diaion beads. Also, the incubation period before extraction may not have been sufficient 
to allow production of the active compounds.  
 
Conclusion 
 
Additional research must be conducted on the two bacteria and their extracts in 
order to determine their level of biological activity. HPLC and NMR indicate possibly 
interesting compounds that are worth pursuing. Bacteria should be regrown in 125 mL 
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cultures and incubated for two weeks to completely replicate the method used to grow the 
bacteria with the original active fractions. There is a possibility that the bacteria did not 
produce the active compounds in the larger volume of media. Another explanation is that 
the larger volume needed a longer incubation period in order to produce the compound. 
In addition to the 125 mL cultures, the bacteria can be grown again in 500 mL cultures 
with a longer incubation period such as three or four weeks. The bacteria should then 
undergo the combined extraction/fractionation step described in the methods section. 
Special attention should be given to dissolving the fractions and whether or not there are 
solubility issues. The extracts and fractions should be tested in the disc diffusion assay, 
the 96 well bioassay, and BioMAP. Testing them against parasites would be of interest, 
because of their probable structural similarity to ornidazole, an anti-parasitic drug.  
If any fractions demonstrate activity against bacteria, or parasites, compound 
isolation should follow. Active fractions should be isolated using HPLC. Isolated 
compounds should be run on NMR, IR and HPLC-MS to determine their structures. 
These spectra will aid in determining whether or not the two active compounds are the 
same, and if they are analogs of ornidazole.  
In order to make the study more thorough, the genomes of the two bacteria can be 
sequenced. This could determine the genera of the bacteria and possibly the species if 
they are previously discovered bacteria. Research looking into the mechanism used by 
the antibiotic compound can also be conducted. Eventually, the compounds can be 
synthetically altered to determine if there is a more potent structure. If the strength of the 
compound is comparable to known antibiotics, the antibacterial may move on to clinical 
trials.    
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